04. October 2017

A Capsugel paper on the search for physiologically unobjectionable coloring agents for pharmaceutical drug formulations in capsules. Comparative analysis between the caplet and capsules where capsules are shown to shorten development times. Download

14. July 2017

QbD applied through scientific approaches to the development and finalisation of LBF commercial processes can shorten project timelines while reducing risks and gaining valuable product knowledge.

10. February 2017

Introduction Rapid and consistent in-vivo drug dissolution is critical for drug absorption. In-vitro dissolutions tests are used to predict in-vivo disintegration and dissolution properties of drug products. The in-vitro disintegration and dissolution times of tablets and capsules can vary signi cantly based on their composition and processing. Though small differences in-vitro dissolution are not expected to result in signi cant in-vivo performance differences, the slight in-vitro dissolution...

08. October 2016

Capsugel recently announced the launch of its Vcaps® Enteric capsules, a new functional capsule technology that achieves enteric protection and delayed release without the need for functional coating. The new capsules provide Capsugel’s customers with another solution for intrinsically enteric delivery, complementing the company’s enTRinsic™ Drug Delivery Technology launched in late 2015. Incorporating enteric polymers to form the primary capsule structure is a breakthrough in drug...

05. July 2016

Kaat Bracquiné, quality and regulatory affairs, Capsugel explains how to achieve compliance with the new EU guidelines for excipient GMPs. Last year, the European Union published new guidelines (2015/C 95/02) that require the pharmaceutical industry to demonstrate appropriate excipient Good Manufacturing Practices (GMPs) through a formalised risk assessment. As of the implementation deadline in March 2016, pharmaceutical companies should have conducted these formalised risk assessments and...

01. March 2016

The emerging trends in the combinatorial chemistry and drug design have led to the development of drug candidates with poor water solubility. Issues associated with poor solubility can lead to low bioavailability, resulting in suboptimal drug delivery. About 40% of drugs with market approval and nearly 90% of molecules in the discovery pipeline are poorly water-soluble. With the advent of various insoluble drug delivery technologies, the challenge to formulate poorly water-soluble drugs can be...

09. September 2015

A powerful alternative for pharmaceutical dosage forms Polymer choices in pharmaceutical dosage forms have always been a balancing act between performance and development time, and historically has been shaped by the interactions of gelatin. The first generation of HPMC capsules, which relied on a secondary gelling agent, were recognized by formulators as having issues with dissolution performance and product stability. Fortunately, new scientific discoveries in polymers and capsule...

03. June 2015

See more at: http://www.drug-dev.com/Main/Back-Issues/CAPSULE-TECHNOLOGY-Enteric-Capsule-Drug-Delivery-T-941.aspx#sthash.afpY2QLf.dpuf

27. March 2015

By Gareth MacDonald+, 26-Mar-2015 Capsugel will invest $25m (€22m) to expand production of vegetarian-friendly drug and food supplement capsules. http://www.in-pharmatechnologist.com/Drug-Delivery/Capsugel-invests-25m-in-vegetarian-drug-capsules

12. January 2015

By Dan Stanton+, 12-Jan-2015 Capsugel has acquired a technology platform which uses ionic liquids to enhance the solubility of lipid-based drug delivery systems. http://www.in-pharmatechnologist.com/Drug-Delivery/Capsugel-buys-ionic-liquid-tech-IP-to-up-lipid-based-drug-solubility